Literature DB >> 23112885

Neoadjuvant Therapy in Clinical Stage II Pancreatic Adenocarcinoma.

Alexandra Snyder1, Peter Allen, Ali Shamseddine, Ali Haydar, Mohamed Eloubeidi, Walid Faraj, Mohamed Khalife, Sally Temraz, Ashwaq El-Olayan, David P Kelsen, Fadi El-Merhi, Mohamed Naghy, Leonard B Saltz, Ghassan K Abou-Alfa, Eileen M O'Reilly.   

Abstract

Entities:  

Year:  2012        PMID： 23112885      PMCID： PMC3481149     

Source DB:  PubMed          Journal:  Gastrointest Cancer Res        ISSN： 1934-7820


× No keyword cloud information.
  43 in total

1.  Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement.

Authors:  Mark P Callery; Kenneth J Chang; Elliot K Fishman; Mark S Talamonti; L William Traverso; David C Linehan
Journal:  Ann Surg Oncol       Date:  2009-04-24       Impact factor: 5.344

2.  Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group.

Authors:  J H Klinkenbijl; J Jeekel; T Sahmoud; R van Pel; M L Couvreur; C H Veenhof; J P Arnaud; D G Gonzalez; L T de Wit; A Hennipman; J Wils
Journal:  Ann Surg       Date:  1999-12       Impact factor: 12.969

3.  Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene.

Authors:  A J Whelan; D Bartsch; P J Goodfellow
Journal:  N Engl J Med       Date:  1995-10-12       Impact factor: 91.245

4.  Cancer risks in BRCA2 mutation carriers.

Authors: 
Journal:  J Natl Cancer Inst       Date:  1999-08-04       Impact factor: 13.506

5.  Very high risk of cancer in familial Peutz-Jeghers syndrome.

Authors:  F M Giardiello; J D Brensinger; A C Tersmette; S N Goodman; G M Petersen; S V Booker; M Cruz-Correa; J A Offerhaus
Journal:  Gastroenterology       Date:  2000-12       Impact factor: 22.682

6.  High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families.

Authors:  A Borg; T Sandberg; K Nilsson; O Johannsson; M Klinker; A Måsbäck; J Westerdahl; H Olsson; C Ingvar
Journal:  J Natl Cancer Inst       Date:  2000-08-02       Impact factor: 13.506

7.  Prognostic value of microsatellite instability in resectable pancreatic cancer.

Authors:  Bunzo Nakata; Yan Qing Wang; Masakazu Yashiro; Nobuaki Nishioka; Hiroaki Tanaka; Masaichi Ohira; Tetsuro Ishikawa; Hiroji Nishino; Kosei Hirakawa
Journal:  Clin Cancer Res       Date:  2002-08       Impact factor: 12.531

8.  The diagnosis of pancreatic cancer by endoscopic ultrasonography.

Authors:  K Yasuda; H Mukai; S Fujimoto; M Nakajima; K Kawai
Journal:  Gastrointest Endosc       Date:  1988 Jan-Feb       Impact factor: 9.427

9.  BRCA2 germline mutations in familial pancreatic carcinoma.

Authors:  Stephan A Hahn; Bill Greenhalf; Ian Ellis; Mercedes Sina-Frey; Harald Rieder; Birgit Korte; Berthold Gerdes; Ralf Kress; Andreas Ziegler; John A Raeburn; Donata Campra; Robert Grützmann; Helga Rehder; Matthias Rothmund; Wolff Schmiegel; John P Neoptolemos; Detlef K Bartsch
Journal:  J Natl Cancer Inst       Date:  2003-02-05       Impact factor: 13.506

10.  A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.

Authors:  John P Neoptolemos; Deborah D Stocken; Helmut Friess; Claudio Bassi; Janet A Dunn; Helen Hickey; Hans Beger; Laureano Fernandez-Cruz; Christos Dervenis; François Lacaine; Massimo Falconi; Paolo Pederzoli; Akos Pap; David Spooner; David J Kerr; Markus W Büchler
Journal:  N Engl J Med       Date:  2004-03-18       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.